Abstract
I read with interest the article 'Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges' [...].
Highlights
I read with interest the article ‘Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges’ [1]
The authors’ assertion that ‘Certainly, high TMB and neoantigen load have been noted to predict the response to immunotherapies, including anti-PD-1 therapy in melanoma, non-small-cell lung carcinoma’ is not supported by the reference provided—an article by Topalian et al [2]—which mentions neither tumour mutational burden (TMB) nor neoantigen load
A better reference might have been a retrospective review published by Goodman et al in 2017 [3] in which 151 immunotherapy-treated patients who had undergone TMB assessment were analysed, and a linear correlation between higher TMB and better outcome parameters was identified
Summary
Comment on: Jilkova, Z.M.; et al “Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
